Alyeska Investment Group L.P. Takes $1.40 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)

Alyeska Investment Group L.P. purchased a new position in Upstream Bio, Inc. (NASDAQ:UPB) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 85,000 shares of the company’s stock, valued at approximately $1,397,000.

Several other institutional investors also recently bought and sold shares of the business. US Bancorp DE bought a new position in Upstream Bio in the fourth quarter worth about $27,000. Legal & General Group Plc purchased a new stake in Upstream Bio during the fourth quarter valued at approximately $28,000. Summit Investment Advisors Inc. acquired a new stake in Upstream Bio in the fourth quarter valued at approximately $30,000. Tower Research Capital LLC TRC purchased a new position in Upstream Bio in the fourth quarter worth $47,000. Finally, Corebridge Financial Inc. acquired a new position in shares of Upstream Bio during the fourth quarter worth $142,000.

Upstream Bio Price Performance

Upstream Bio stock opened at $8.21 on Wednesday. Upstream Bio, Inc. has a 1-year low of $5.14 and a 1-year high of $29.46. The business has a fifty day moving average price of $7.99 and a 200-day moving average price of $13.84.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). Research analysts anticipate that Upstream Bio, Inc. will post -4.3 EPS for the current fiscal year.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.